In the treatment of Parkinson’s disease (PD), medications such as levodopa, DOPA agonists (non-ergotamine), MAO inhibitors, and COMT inhibitors are initially used in monotherapy, and then in combination as the disease progresses. This evidence concerns the gene COMT and Parkinson disease.